Trastuzumab

Generic Name: Trastuzumab

Brand Names: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue

Drug Type: Biotech

Chemical Formula: -

CAS Number: 180288-69-1

Unique Ingredient Identifier: P188ANX8CK

Background: Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...

Indication: For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...

Associated Conditions: Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer

Associated Therapies: -

Clinical Trials

The Clinical Study of Intratumoral and Peritumoral Radiomics Based on

This study explores the clinical value of combining intratumoral and peritumoral radiomic features based on DCE-MRI with clinicopathological characteristics for preoperative HER-2 expression status prediction in breast cancer, highlighting the importance of tumor heterogeneity in guiding treatment decisions.

insideprecisionmedicine.com

2 months ago

Personalized Medicine: Past, Present, and Future

In 2000, President Clinton celebrated the first survey of the human genome, predicting it would revolutionize medicine. Despite initial skepticism, personalized medicine gained traction, driven by advancements in diagnostics and targeted therapies. Challenges remain in regulatory frameworks and healthcare infrastructure, but the promise of personalized, predictive, and preventive medicine continues to evolve.

mdanderson.org

2 months ago

Funda Meric-Bernstam, M.D., elected to National Academy of Medicine

Funda Meric-Bernstam, MD, chair of Investigational Cancer Therapeutics at MD Anderson, was elected to the National Academy of Medicine for contributions to precision oncology, therapeutics development, and leading practice-changing clinical trials. She has notably advanced antibody-drug conjugates, leading to FDA approvals and improved cancer treatment outcomes. Meric-Bernstam has also developed novel approaches to overcoming resistance in targeted therapies and ADCs, authored over 600 peer-reviewed papers, and received over $23 million in research funding.

koreabiomed.com

3 months ago

Prestige BioPharma secures EC approval for Herceptin biosimilar Tuznue

Prestige BioPharma received final EC approval for its Herceptin biosimilar, Tuznue, following EMA's CHMP recommendation. Tuznue is the third trastuzumab biosimilar approved in Europe, with Prestige aiming to expedite marketing for its Avastin biosimilar, HD204. Tuznue's approval marks Prestige's first milestone, with revenue expected post-launch. CEO Park So-yeon plans to meet potential partners at CPHI Milan 2024 and develop 15 biosimilar pipelines.

urotoday.com